Bioaffinity Technologies Inc (BIAF)

$0.25 +0.00 (1.22%)
Market Cap 6.80M
Revenue (ttm) 9.36M
Net Income (ttm) -9.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -96.58%
Debt to Equity Ratio -0.04
Volume 535,777
Avg Vol 1,356,410
Day's Range N/A - N/A
Shares Out 28.47M
Stochastic %K 48%
Beta 2.52
Analysts Hold
Price Target $6.00

Company Profile

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, incl...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 210 698 5334
Address:
3300 Nacogdoches Road, Suite 216, San Antonio, United States
Djaban
Djaban Sep. 9 at 8:57 PM
$BIAF https://www.marketwatch.com/press-release/case-study-cypath-r-lung-identifies-lung-cancer-in-patient-with-difficult-to-diagnose-ground-glass-pulmonary-nodules-62fd85af?mod=mw_quote_news_seemore
0 · Reply
Logic102
Logic102 Sep. 5 at 1:02 PM
$BIAF When does the bleeding stop? Massive potential for peanuts here.
1 · Reply
Abdulloh2323
Abdulloh2323 Sep. 3 at 2:12 PM
$BIAF 🚀
0 · Reply
Havoc1649
Havoc1649 Sep. 2 at 4:10 PM
$BIAF New 8K is out today. I’m trying to find a link to a summary. Please post it if you find one.
1 · Reply
mechaniker06
mechaniker06 Sep. 2 at 6:21 AM
$BIAF imagine if they would sell this to hospitals in china and india, over 2B people and 40% smoke how much money they could make? this could be a 50 buck stock with revenue
2 · Reply
TheRealRazingCane
TheRealRazingCane Aug. 29 at 8:15 PM
$BIAF The company reported that test revenue had increased roughly 62% for the first 1/2 of the year, to about $320K in the most recent quarterly earnings. At roughly $2K per test, that's roughly one test per day. That's why they don't report the actual test volume - my bet is that it is embarrassingly small. It's easy to get large percentage increases when that is the case.
1 · Reply
TheRealRazingCane
TheRealRazingCane Aug. 29 at 8:10 PM
$BIAF This stock's history shows an average loss of 15.8% for Sept., 8.3% for October, 3.8% for November, and a whopping 25.8% for December. Patience is not always a virtue...IT has only been positive in Sept/Oct/Nov about 33% of the time, and never been positive in December.
0 · Reply
ImTheDudeMan
ImTheDudeMan Aug. 26 at 9:50 PM
$BIAF
0 · Reply
FusionFuturist
FusionFuturist Aug. 23 at 7:27 AM
$BIAF bioAffinity Technologies Inc is a diagnostic company with early stage commercialization
0 · Reply
ExecutiveEdge
ExecutiveEdge Aug. 22 at 3:30 PM
TGL Crypto treasury plays are lighting up, and TGL is still hiding under $1 with a true value near $11. AI + blockchain product launch in Q3, 2.7M+ users, and a float so small it’s been fully rotated. This is exactly how massive squeezes start. $BIAF $REVB $RNAZ $LUNR
0 · Reply
Latest News on BIAF
bioAffinity Technologies Appoints New Members to Board of Directors

Aug 18, 2025, 8:00 AM EDT - 22 days ago

bioAffinity Technologies Appoints New Members to Board of Directors

bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

Aug 14, 2025, 4:15 PM EDT - 26 days ago

bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

bioAffinity Technologies Reports Second Quarter 2025 Results

Aug 14, 2025, 8:00 AM EDT - 26 days ago

bioAffinity Technologies Reports Second Quarter 2025 Results

bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

Aug 13, 2025, 9:25 AM EDT - 27 days ago

bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales

Aug 13, 2025, 8:00 AM EDT - 27 days ago

bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales

Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results

Jul 29, 2025, 8:00 AM EDT - 6 weeks ago

Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results

Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic

Jul 22, 2025, 9:00 AM EDT - 7 weeks ago

Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic

bioAffinity Technologies Announces Notification of China Patent Award for Company's Noninvasive Lung Cancer Diagnostic

Jul 15, 2025, 9:00 AM EDT - 2 months ago

bioAffinity Technologies Announces Notification of China Patent Award for Company's Noninvasive Lung Cancer Diagnostic

bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference

Jun 26, 2025, 9:00 AM EDT - 2 months ago

bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference

bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy

Jun 24, 2025, 9:00 AM EDT - 2 months ago

bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy

bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

Jun 11, 2025, 9:00 AM EDT - 3 months ago

bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics

May 28, 2025, 9:00 AM EDT - 3 months ago

bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics

bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer

May 20, 2025, 9:00 AM EDT - 4 months ago

bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer

bioAffinity Technologies Reports First Quarter 2025 Results

May 15, 2025, 8:30 AM EDT - 4 months ago

bioAffinity Technologies Reports First Quarter 2025 Results

Independent White Paper Highlights Real-World Impact of bioAffinity Technologies' CyPath® Lung in Diagnosing Early-Stage Lung Cancer

May 8, 2025, 9:00 AM EDT - 4 months ago

Independent White Paper Highlights Real-World Impact of bioAffinity Technologies' CyPath® Lung in Diagnosing Early-Stage Lung Cancer

WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering

May 7, 2025, 1:15 PM EDT - 4 months ago

WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering

bioAffinity Technologies Announces Closing of $3.25 Million Offering

May 7, 2025, 1:00 PM EDT - 4 months ago

bioAffinity Technologies Announces Closing of $3.25 Million Offering

WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering

May 6, 2025, 10:30 AM EDT - 4 months ago

WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering

bioAffinity Technologies Announces Pricing of $3.25 Million Offering

May 6, 2025, 9:25 AM EDT - 4 months ago

bioAffinity Technologies Announces Pricing of $3.25 Million Offering

bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

Apr 17, 2025, 9:15 AM EDT - 5 months ago

bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

Mar 31, 2025, 9:28 AM EDT - 5 months ago

bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

Case Study: bioAffinity Technologies' CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

Mar 26, 2025, 9:00 AM EDT - 5 months ago

Case Study: bioAffinity Technologies' CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

Case Study: bioAffinity Technologies' Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence

Mar 19, 2025, 9:00 AM EDT - 6 months ago

Case Study: bioAffinity Technologies' Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence

Physicians' Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer

Mar 13, 2025, 9:00 AM EDT - 6 months ago

Physicians' Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer

bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

Mar 6, 2025, 8:00 AM EST - 6 months ago

bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

Feb 26, 2025, 12:10 PM EST - 6 months ago

WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

Feb 26, 2025, 11:30 AM EST - 6 months ago

bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

Feb 25, 2025, 11:05 AM EST - 7 months ago

WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

Feb 25, 2025, 9:58 AM EST - 7 months ago

bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic

Jan 22, 2025, 8:00 AM EST - 8 months ago

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic

bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung

Jan 13, 2025, 8:00 AM EST - 8 months ago

bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jan 10, 2025, 9:00 AM EST - 8 months ago

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ENLV

Join bioAffinity Technologies' Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19

Dec 17, 2024, 8:00 AM EST - 9 months ago

Join bioAffinity Technologies' Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19

bioAffinity Technologies Set for Continued Expansion in 2025

Dec 12, 2024, 8:00 AM EST - 9 months ago

bioAffinity Technologies Set for Continued Expansion in 2025

bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024

Nov 14, 2024, 8:00 AM EST - 10 months ago

bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024

bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development

Nov 4, 2024, 8:00 AM EST - 11 months ago

bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development

bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung

Oct 30, 2024, 8:00 AM EDT - 11 months ago

bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung

WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement

Oct 21, 2024, 11:39 AM EDT - 11 months ago

WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement

bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement

Oct 21, 2024, 10:45 AM EDT - 11 months ago

bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement

WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement

Oct 18, 2024, 2:57 PM EDT - 11 months ago

WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement

bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement

Oct 18, 2024, 12:45 PM EDT - 11 months ago

bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement

bioAffinity's CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines

Oct 16, 2024, 8:00 AM EDT - 11 months ago

bioAffinity's CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines

bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer

Oct 10, 2024, 8:00 AM EDT - 11 months ago

bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer

bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test

Oct 9, 2024, 8:00 AM EDT - 11 months ago

bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test

Peer-Reviewed Study: bioAffinity Technologies' CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis

Sep 18, 2024, 8:00 AM EDT - 1 year ago

Peer-Reviewed Study: bioAffinity Technologies' CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis

bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO

Aug 23, 2024, 5:15 PM EDT - 1 year ago

bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO

bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales

Aug 14, 2024, 9:25 AM EDT - 1 year ago

bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales

WallachBeth Capital Announces Closing of bioAffinity Technologies Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

Aug 5, 2024, 2:00 PM EDT - 1 year ago

WallachBeth Capital Announces Closing of bioAffinity Technologies Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

Aug 5, 2024, 1:17 PM EDT - 1 year ago

bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

WallachBeth Capital Announces bioAffinity Technologies Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

Aug 2, 2024, 10:00 AM EDT - 1 year ago

WallachBeth Capital Announces bioAffinity Technologies Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

Djaban
Djaban Sep. 9 at 8:57 PM
$BIAF https://www.marketwatch.com/press-release/case-study-cypath-r-lung-identifies-lung-cancer-in-patient-with-difficult-to-diagnose-ground-glass-pulmonary-nodules-62fd85af?mod=mw_quote_news_seemore
0 · Reply
Logic102
Logic102 Sep. 5 at 1:02 PM
$BIAF When does the bleeding stop? Massive potential for peanuts here.
1 · Reply
Abdulloh2323
Abdulloh2323 Sep. 3 at 2:12 PM
$BIAF 🚀
0 · Reply
Havoc1649
Havoc1649 Sep. 2 at 4:10 PM
$BIAF New 8K is out today. I’m trying to find a link to a summary. Please post it if you find one.
1 · Reply
mechaniker06
mechaniker06 Sep. 2 at 6:21 AM
$BIAF imagine if they would sell this to hospitals in china and india, over 2B people and 40% smoke how much money they could make? this could be a 50 buck stock with revenue
2 · Reply
TheRealRazingCane
TheRealRazingCane Aug. 29 at 8:15 PM
$BIAF The company reported that test revenue had increased roughly 62% for the first 1/2 of the year, to about $320K in the most recent quarterly earnings. At roughly $2K per test, that's roughly one test per day. That's why they don't report the actual test volume - my bet is that it is embarrassingly small. It's easy to get large percentage increases when that is the case.
1 · Reply
TheRealRazingCane
TheRealRazingCane Aug. 29 at 8:10 PM
$BIAF This stock's history shows an average loss of 15.8% for Sept., 8.3% for October, 3.8% for November, and a whopping 25.8% for December. Patience is not always a virtue...IT has only been positive in Sept/Oct/Nov about 33% of the time, and never been positive in December.
0 · Reply
ImTheDudeMan
ImTheDudeMan Aug. 26 at 9:50 PM
$BIAF
0 · Reply
FusionFuturist
FusionFuturist Aug. 23 at 7:27 AM
$BIAF bioAffinity Technologies Inc is a diagnostic company with early stage commercialization
0 · Reply
ExecutiveEdge
ExecutiveEdge Aug. 22 at 3:30 PM
TGL Crypto treasury plays are lighting up, and TGL is still hiding under $1 with a true value near $11. AI + blockchain product launch in Q3, 2.7M+ users, and a float so small it’s been fully rotated. This is exactly how massive squeezes start. $BIAF $REVB $RNAZ $LUNR
0 · Reply
ZacksResearch
ZacksResearch Aug. 21 at 7:00 PM
$BIAF down 27.4% in a month — is there light at the end of the tunnel? 🌫️ Despite a revenue drop from discontinuing pathology services, CyPath Lung testing revenue surged 62.3% in the first half of 2025, signaling growing physician adoption. However, the net loss widened due to non-cash expenses and costs from a public offering. 📉 Opportunity assessment here 👉 https://www.zacks.com/stock/news/2741163/biaf-stock-down-following-q2-earnings-despite-cypath-lung-growth?cid=sm-stocktwits-2-2741163-body-8954&ADID=SYND_STOCKTWITS_TWEET_2_2741163_BODY_8954
0 · Reply
ZacksResearch
ZacksResearch Aug. 21 at 6:00 PM
$BIAF drops on Q2 earnings — but here’s the twist 👀 Losses widened, yet CyPath Lung adoption is climbing and expansion into new markets is gaining traction. Full breakdown here 👉 https://www.zacks.com/stock/news/2741163/biaf-stock-down-following-q2-earnings-despite-cypath-lung-growth?cid=sm-stocktwits-2-2741163-teaser-8953&ADID=SYND_STOCKTWITS_TWEET_2_2741163_TEASER_8953
0 · Reply
Justerik
Justerik Aug. 21 at 12:35 AM
$BIAF
0 · Reply
TheWolfOfCalgary
TheWolfOfCalgary Aug. 19 at 6:50 PM
$BIAF it’s on the rise yoooo 🚀
0 · Reply
SPYmyQQQ
SPYmyQQQ Aug. 19 at 5:07 PM
🎯 TP hit — trade closed ✅ 💊 $BIAF 🗓️ Aug 18, 2025 🎯 Entry: $0.2331 ✅ Hit at: $0.2684 📊 P/L: +15.14% 📨 Signal was given on Aug 18, 2025. Join to receive instantly!
0 · Reply
TheRealRazingCane
TheRealRazingCane Aug. 19 at 1:52 PM
$BIAF Finally showing some constructive price action. This could be setting up a double bottom low from a technical perspective, after a solid month of downside price action. Perhaps this will be the first August BIAF closes higher at the end of the month than it started the month at.
1 · Reply
Bonecollecror
Bonecollecror Aug. 18 at 8:07 PM
$BIAF This stock has smashed me - down from 0.35 Gutted 😞
2 · Reply
Logic102
Logic102 Aug. 18 at 11:58 AM
$BIAF This stock is really beaten down. If the company can execute, this is the steal Lottery Ticket buy of 2025. Amazing that, even with revenue and a lot of promise this Market Cap is less than a bench warmer Pro sports salary.
0 · Reply
SPYmyQQQ
SPYmyQQQ Aug. 18 at 11:11 AM
🚨 New Signal ✅ 💊 $BIAF 🗓️ Aug 18, 2025 🎯 Entry: $0.2331 🎯 Target: $0.2684 (+15.14%)
0 · Reply
R_NW
R_NW Aug. 17 at 2:31 PM
$BIAF I wish they would sell the company, so they would be able to launch in all 52 states and the ROW now, rather than dragging it out.
0 · Reply
nanoled2020
nanoled2020 Aug. 15 at 5:00 PM
$BIAF can they now reverse split at any moment?
1 · Reply
Logic102
Logic102 Aug. 15 at 11:52 AM
$BIAF In small biotech with a novel treatment or test you see a hockey stick ramp in sales. It takes some time and then an explosion if sales. We are on target. The stock is severely beaten down for the opportunity. No brainer Buy.
2 · Reply